TRUDEAU

on the Rise

TRUDEAU INSTITUTE
TRUDEAU IS:
A nimble, mission-directed research institute positioned to accelerate biomedical advances against life-threatening infectious diseases. Our special teams empower the pursuit of innovative solutions through efficient collaboration and select strategic partnerships.
Dear Friends,

TODAY, IN OUR 135TH YEAR, Trudeau researchers are on the cusp of a new era of discovery. We have successfully recruited five new Ph.D.s, who will seek new treatments for drug-resistant tuberculosis, establish vaccine protocols to combat Zika and other emerging viruses, and build new expertise in the growing threat of tick-borne illnesses.

To fight most effectively as we deploy our superb special-focus teams, we’ve changed the very way we work. While we remain an independent biomedical research institution, we are intensively sharing our expertise with other world-class institutions to discover biomedical breakthroughs together. The growing breadth and depth of biomedical science demands this highly interactive, multi-disciplinary approach. By positioning Trudeau as a specialized biotechnology hub in a strategic partnership network, we can leverage the strengths of many institutions against infectious diseases—especially those that attack through the most common routes of infection and evade our immune defenses.

The core of our strategy, the Trudeau Research Network, is already expanding our reach and accelerating our progress. In the past two years, we have attracted partners from the Walter Reed Army Institute of Research, SUNY Upstate Medical University, Albert Einstein College of Medicine, the Texas Biomedical Research Institute and several other leading organizations to discover treatments for newly emergent diseases spread by mosquitoes and ticks, and to continue our long-running work in defusing respiratory-borne illness, especially tuberculosis and influenza.

A breakthrough in any of these areas will have untold impact on the human experience. Millions of people are infected, and die, from these diseases each year. These are the great public health challenges of our time—but we need your help to ensure these discoveries come to light. As Trudeau continues to rise, philanthropic support is urgently needed to accelerate our advances. We are actively seeking leadership funding for our Innovation Fund for Tuberculosis R&D, and our Innovation Fund for Tick-Borne Infections.

On behalf of all 60 of us at Trudeau—our growing team of dedicated researchers, technicians and support staff—I want to thank you for your generosity. I urge you to join with us and take action to leave a better world for generations to come.

Sincerely,

Atsuo Kuki, Ph.D.
President & Director
TB still remains the world’s leading infectious disease

- **2 billion**: Number of people whose lungs have been infected by TB
- **1.6 million**: Number of people killed by TB in 2018
- **10 million**: New acute TB cases every year
- **458,000**: New multi-drug-resistant (MDR) TB cases in 2018
- **4% - 7%**: Percentage of developing nation GDP consumed by TB
Some of the most important advances in tuberculosis research made in the 20th century resulted from work done at the Trudeau Institute. Our job isn’t done yet.

Between 2000 and 2018, 58 million people were cured of tuberculosis. But because of the sheer scale of this ongoing epidemic, and the lengthy, arduous treatment it requires, TB still remains the world’s leading infectious disease: In 2018 alone, it killed 1.6 million people, more than due to HIV and influenza combined.

The most pressing challenge on that front is drug-resistant tuberculosis: tuberculosis bacteria that remain even after normal anti-TB treatment, resulting in a disease that is difficult to cure—fewer than a third of patients with the most virulent form of drug-resistant TB recover—and expensive to treat, with a typical 32-month course of treatment costing more than $675,000.

We’re deploying our long-standing expertise in tuberculosis, immunology, vaccines and genetics to fight this scourge—and deploying new fronts, also, in fields such as target-based drug discovery and computational chemogenomics (see story, following page). Trudeau is growing: We’re adding new principal investigators and researchers in our TB program with academic, biotech/pharma and clinical research expertise, bolstering our professional staff who have decades of experience.
Last year, public health experts estimate a half-million people were infected with a drug-resistant strain of tuberculosis, already the world’s deadliest infectious disease. Behind this rapidly growing number of recalcitrant TB cases: Patients often don’t complete the six-month, four-drug course of TB treatment, effectively allowing drug-resistant strains to emerge.

The result is a global health crisis that threatens to derail decades of advances in treating TB, and one for which scientists are scrambling for a faster, more potent—and less expensive—cure.

A pair of Trudeau scientists, Felix Sheinerman and Brian Weinrick, are spearheading an effort to identify drugs and molecules originally developed for other uses that may also be effective against tuberculosis. Sheinerman is using the latest computational methods to find good candidates, while Weinrick, an experienced TB researcher, is putting each through a rigorous evaluation.

And because many of the compounds they’re investigating have already been tested for safety, it could drastically cut the time needed to get an improved treatment to patients.
To Sheinerman, the math is on Trudeau’s side. Of the tuberculosis bacterium’s 4,000 genes, just 400 or so are critical to its ability to survive in human lungs.

Over the past century, though, more than 20,000 drugs have been developed and tested for safety in humans—some of which may prove fatal to the pathogen that causes TB. “The challenge is to say, ‘Look, even though that drug was never tested on this TB protein, it’s known to be active on a protein that is structurally very similar to one in TB,’” Sheinerman says.

Sheinerman’s expertise, in a field known as computational chemogenomics, draws on 3D modeling techniques that can determine whether a particular molecule is likely to interact with any of those 400 TB proteins. If a match seems promising, Sheinerman alerts Weinrick, who then puts the compound through a battery of tests to see if it has real-world potential.

With just a few months of testing under their belts, as many as 10 percent of the compounds Sheinerman and Weinrick are investigating appear to be of interest. A typical drug discovery process, on the other hand, results in failure rates of 99 percent or more. “The existing drug discovery process is very inefficient,” Sheinerman says. “And that’s in large part the reason why modern drug discovery is not delivering.”

Seeing something merely interesting, though, is hardly the end of the discovery process. The team’s job is to understand why a promising compound works, and refine it to be even more effective—ultimately leading to a treatment that can be patented, licensed to a pharmaceutical company, clinically tested and deployed. Ideally, they’d discover a drug that significantly shortens that half-year treatment period—even cutting it by 2 or 3 months, Weinrick says, “would be a huge win.”

Weinrick came to Trudeau in 2017 after working for more than a decade with one of the world’s foremost TB researchers, William Jacobs (he was once dubbed the “TB Terminator”). For Weinrick the quest is personal: While teaching in Eritrea with the Peace Corps, a fellow teacher was hospitalized with TB. “That really illuminated the societal impact of this disease, on the places that are least able to afford it,” he says. “The personal impact is awful, but it’s a societal drain also. Tuberculosis stops people from contributing while they’re in their prime. TB reinforces the poverty cycle in the places where it is most common.”

Sheinerman, also recruited to Trudeau in 2017, is an example of how we’re bringing new technical expertise into the field. As with Weinrick, he was drawn by the allure of working on a problem that could bear immediate fruit.

“It was important to me to see that this work has a direct relevance to humans,” Sheinerman says. “I think it’s very likely that the next breakthrough in tuberculosis won’t come from Big Pharma, but from a smaller organization such as Trudeau. And I think we’re taking the right approach, with the right ingredients for success.”
Seeking solutions for emerging pathogens, such as the Zika virus

1 billion
Number of people infected each year by mosquito-borne diseases

1 million
Number of people who die each year of mosquito-borne diseases

27,388
Number of mosquito- and tick-borne disease cases in U.S., 2004

96,075
Number of mosquito- and tick-borne disease cases in U.S., 2016

17%
Percentage of infectious illnesses caused by mosquito- and tick-borne disease annually.

Source: World Health Organization, Centers for Disease Control and Prevention
Trudeau is the partner researchers trust to translate lab breakthroughs into patient victories.

For 135 years, Trudeau has been a leader in combatting persistent infectious diseases. Our legacy provides the foundation for what we are now: A nimble, independent biomedical laboratory that is a valuable contributor in the fight against newly emerging infectious threats.

That track record engenders confidence. Today, some of the world’s most prestigious research institutes are seeking to tap the expertise we’ve amassed at our 75,000-square-foot research laboratory in the Adirondacks. These partnerships are at the core of the Trudeau Research Network. Together, we’re working to cure drug-resistant infections and find solutions for emerging pathogens, such as the Zika virus, for which no therapies exist at all.

As part of this model, leading biomedical researchers in New York, the nation and the world discover the building blocks needed to defuse emerging infectious diseases and other threats. They then leverage Trudeau’s immunology expertise and biocontainment laboratory to translate those discoveries into superior candidates that merit clinical trials, and subsequently, from this stronger platform, deliver real-world treatments.
A virus that leaves no trace in many people it infects—and often results in little more than a fever or a rash—wouldn’t seem a prime candidate to inspire a global race to find a cure.

But Zika isn’t like most viruses. Because while most people who encounter it are barely harmed, it is a terror to pregnant women. Zika can cause a host of potentially cataclysmic birth defects, and no vaccine or medicine exists to thwart it.

Yet.

With the backing of a $1.2 million grant from the Department of Defense, Trudeau Institute Senior Principal Investigator Marcy Blackman is leading efforts to determine whether a Zika vaccine candidate can block the virus from infecting fetuses in small animal models—and, if so, whether it should move on for further clinical testing elsewhere.

That multi-pronged approach is representative of our efforts to leverage the power of the Trudeau Research Network: The vaccine was developed at the Walter Reed Army Institute of Research, is being tested at Trudeau, and, based on our findings, will be further tested by our Trudeau Research Network plays key role in race to vanquish Zika
partners at the Texas Biomedical Research Institute. Through it all, we’ve worked closely with Stephen Thomas, chief of SUNY Upstate Medical University’s Division of Infectious Diseases and a co-developer of the vaccine. Researchers at the University of Illinois at Chicago are also participating in the project.

“This is something that Trudeau couldn’t have done on its own,” says Blackman, who has been at the Institute since 1999. “But building this powerful collaboration with such accomplished partners makes me confident we can close in on a vaccine far quicker than any of us could have working apart.”

Scientists still aren’t sure why Zika poses such a grave threat to developing fetuses. Blackman has conducted research to see if prior exposure to the virus that causes Dengue fever makes it easier for Zika to pass through the placenta, but that work is still ongoing.

Studies like these are emblematic of Trudeau’s growing focus on translational work. Instead of pursuing basic research, we’re aligning with biomedical partners who can use our expertise in immunology and pathogens while solving imminent threats. To Blackman, it’s a change she welcomes.

“Now, we’re actually involved in the translation to biomedical solutions ourselves,” says Blackman, who finds the collaborative approach accelerates the pace of progress. “So it’s much more satisfying, in that sense.”

At the moment, it’s too early to tell whether the vaccine candidate developed by Walter Reed will be successful in preventing the disease from infecting fetuses. And while the flurry of mainstream headlines around Zika has died down somewhat in recent years—it’s likely that many of the people in the places where it was rampant have already been infected, and developed antibodies to it—that just puts pressure on Blackman and others to have a vaccine candidate ready, when it resurfaces in a new area, and sparks new fears.

Blackman is optimistic that the testing regime she’s developing is a model that holds hope for future collaborations between Trudeau and other partners.

“This is verification that this type of research model will really work,” Blackman says. “It’s hard for one place to be able to do everything. Science has really become huge, very complex, very expensive, and to have experts in different aspects of a certain problem come together is really a very efficient way of accomplishing things.”

Trudeau 3.0: Leveraging our strengths as a specialized biotechnology hub against emerging infectious threats.
Dear Friends of Trudeau,

ON BEHALF OF OUR BOARD OF TRUSTEES, we want to say “thank you” to those who support the research and development currently underway at the Institute. Trudeau has captured the attention of public and private funding partners while establishing a unique network of strategic academic collaborators.

In July, we commemorated the 100th anniversary of the birth of Dr. Francis B. Trudeau, gathering with the Trudeau family and others at the Saranac Laboratory Museum. We returned to Dr. Trudeau’s lab in October, to celebrate its designation as a **Milestones in Microbiology** historic site by the American Society for Microbiology; to mark the occasion and re-affirm our 135-year legacy, TB Principal Investigator Dr. Brian Weinrick co-hosted a day-long science symposium on our campus, where a dozen experts in the field of tuberculosis shared their work.

In June we were challenged by The Cloudsplitter Foundation to raise $100,000 from former and current Trustees to be matched dollar for dollar by the Foundation. We completed the match in four months! To me, this demonstrates a clear vote of confidence from those intimately involved with Trudeau. This money will be applied to our expanding TB research.

All of us on the board are pleased to continue shepherding Trudeau Institute into the future as a sustainable and meaningful research and development platform. We remain especially proud of our role in the community as an important economic partner and we are most grateful for Dr. Atsuo Kuki’s leadership and originality.

Thank you.

Dorothy Swern Federman, Chair
Kip Testwuide, Vice Chair
Governor’s Club
($50,000 to $99,999)
Mr. Irving S. Caplan Trust
Dr. Charles W. McCutchen
The Ambrose Monell Foundation

Second-Century Club
($20,000 to $49,999)
Mr. & Mrs. Benjamin Brewster
Mr. Bruce McLanahan

Founder’s Club
($6,000 to $19,999)
Mr. & Mrs. Alexander W. Dreyfoos
Drs. Jay & Dorothy Federman
Dr. Atsuo Kuki
Mr. & Mrs. Daniel Leff
Ms. Julie A. North & Mr. William V. Fogg
Mr. & Mrs. Jim Sonneborn
Mr. & Mrs. Garry Trudeau
Dr. Tielman Van Vleck

President’s Club
($3,000 to $5,999)
Anonymous
Ms. Courtney Burke
Dr. James C. Frauenthal
Lola & Ray Johnson
Lee & Nancy Keet
Rich & Lorraine McGinn
Dr. Lida Orzech
Julie & Kip Testwuide
Mr. & Mrs. Alexander B. Trevor
The John and Evelyn Trevor Charitable Foundation

Director’s Club
($1,000 to $2,999)
Adirondack Foundation – Evergreen Fund
Mrs. Mary Ann Casey
Mr. Denis Faucher
Mr. John R. Gordon
Mr. George P. Hanscom
Mr. & Mrs. James Hotaling
Sheila Rauch Kennedy
Mr. & Mrs. Donald A. King Jr.
Dr. Airlie C. Lennon
Ms. Nancy Lester
Mr. Lawrence Loeffler
Mr. & Mrs. Clement McGillicuddy
Mrs. Elizabeth Sonneborn
Mr. & Mrs. Konrad Testwuide
Ms. Patricia Y. Tsien & Mr. Thomas Cleveland
Ms. Yi Xue
Mrs. Janet York

Sponsor’s Club
($500 to $999)
Mr. & Mrs. Barry F. Berkov
Mr. & Mrs. Peter W. Bickford
Mr. & Mrs. Joseph Blitt
Jacques & Edwina DeMattos Cormier
Dr. & Mrs. Craig B. Dumond
William & Elaine Fearnside
Mr. & Mrs. Henry A. Fenn
Neil A. (Tony) Holtzman
Dick & Bobbie Leamer
Mr. & Mrs. J. Michael Ritchie
Mr. & Mrs. W. McIlwaine Thompson

Patrons
($250 to $499)
Adirondack Foundation – Mirror Lake Inn Charitable Fund
Ellen & Michael Bettman
Mr. & Mrs. Edward W. Bickford
Mr. William B. Chapin

President and Director Atsuo Kuki celebrates the Saranac Laboratory Museum’s Milestone in Microbiology designation.
Patrons (continued from previous page)
($250 to $499)
Mr. & Mrs. Lee Harrison Corbin
Dr. & Mrs. Vincent A. Fischetti
Mr. & Mrs. Stewart Greenfield
Mr. & Mrs. John F. Heimerdinger
Mr. & Mrs. John Hemphill
Mr. & Mrs. William C. Janeway
Dr. & Mrs. David A. Johnson, M.D.
Mr. & Mrs. David P. Kirstein
Mr. Peter McHugh & Ms. Louise McNamee
Rice Furniture
Ms. Mary Thill & Mr. Mark Wilson
Mrs. Francis B. Trudeau
Mr. & Mrs. Charles S. Von Stade Jr.

Supporters
($100 to $249)
Anonymous
Joe & Ann Armstrong
Mr. Perrin Babcock
Mr. & Mrs. Matthew P. Baker
Bernard & Lois Barrett
Mr. Benjamin L. Chapman
Mr. Thomas H. Delahant
Jacques & Alice De Mattos
Mr. Mike Ernick
Mrs. Dorothy E. Fobare
Mrs. Mabel E. Foote
Mr. & Mrs. Martin Goetz
Betty F. Hunkins
Christopher & Audrey Hyson
Mr. & Mrs. Wayne A. Johnston
Michael & Sandra Kamen
Dr. & Mrs. Woods McCahill
Mr. & Mrs. Eugene Bradley Meyer
Dr. & Mrs. Thomas Minehan
Peter S. Paine Jr.
Paul & Rosemary Reiss
Clyde Baker & Suzanne Rice
Harriet H. Savage
Calvin & Christina Schmeichel
Dr. & Mrs. Craig W. Smith
Mr. & Mrs. Stuart Solomon
Mrs. Elizabeth Sonneborn
Tom & Joan Sonneborn
Judge & Mrs. W. Neil Thomas III
Edward & Patricia Trudeau III
Ms. Michelle B. Trudeau & Dr. Steven G. Potkin
Dr. Kathryn Weld-Brown
Dr. & Mrs. David G. Welch
Mrs. Caroline Welsh
Mr. R.V. Whisnand
Mr. & Mrs. Robert R. Zahm

Friends
($25 to $99)
Rip & Shirley Allen
Lionel & Esther Arlan
Mr. & Mrs. William Bond
Mary & Jack Brennan
Dr. & Mrs. John Cogar
George H. Earle
Mr. Joseph Giordmaine
Ms. Georgia J. Jones
Mr. Rob Kaplan
Mr. Arthur Kirsch
Mr. & Mrs. Gerald Matalcotta
Sandra Mealy
Don & Shirley Morgan
Mr. & Mrs. Arthur G. Olver
Bill Picotte
Larry & Jean Poole
Steven Sonnenberg & Margaret Worden
Robert E. & Amy K. Sweet
Duncan & Delphine Winter
Fran Yardley & Burdette Parks

All Other Contributions
Mr. Darrell Davies
Dr. & Mrs. Richard L. Erenstone
Lionel & Marcia Schuman

IN MEMORY OF
Bickford Family Fund
Mr. & Mrs. Edward W. Bickford
Mr. & Mrs. Peter W. Bickford
Mrs. Mary Ann Casey
Judge & Mrs. W. Neil Thomas III
Mr. & Mrs. John F. Delahant, Jr.
Dr. & Mrs. John F. Delahant
Mrs. Elizabeth Sonneborn
Mr. & Mrs. Edward W. Bickford
Mr. & Mrs. Peter W. Bickford
Mr. & Mrs. Mary Ann Casey
Mr. & Mrs. W. Neil Thomas III
Mr. & Mrs. John F. Delahant, Jr.
Mr. Thomas H. Delahant

IN HONOR OF
Benjamin Brewster
Dr. Tielman Van Vleck
Mr. R.V. Whisnand
Dr. Dorothy Federman
Lionel & Esther Arlan
Dr. Lida Orzeck
Sandy Trevor
Rich & Lorraine McGinn
Patricia Tsien
Robert Zahm
George Hanscom

Maddie’s B-Day from Lucy
Rob Kaplan
Contributions from Corporations, Foundations & Organizations

Adirondack Foundation – Evergreen Fund
Adirondack Foundation – Keet Family Fund
Adirondack Foundation – McLanahan Family Fund
Adirondack Foundation – Mirror Lake Inn Charitable Fund
Adirondack Foundation – Trevor Fund for Trudeau Institute
The Ambrose Monell Foundation
Bickford Family Fund
Bionique Testing Laboratories Inc.
Exxon Mobil Foundation
The Stewart & Constance Greenfield Foundation
The Janet Stone Jones Foundation
Jewish Communal Fund
The McCutchen Foundation
The McMeel Family Foundation
Mountaintop Foundation
Rice Furniture
Ruthie’s Run
The Sooner Foundation
The Spiritus Gladius Foundation
Staritch Foundation, Inc.
The John & Evelyn Trevor Charitable Foundation
Vanguard Charitable Endowment Program

*Received in 2017

Although the greatest possible care has been taken preparing this recognition to our donors, there is a possibility of inaccuracies. If any are noted, please accept our apology and forward corrections.

Office of Institutional Advancement
Trudeau Institute
154 Algonquin Avenue
Saranac Lake, NY 12983
pbabcock@trudeauinstitute.org

THE FOUNDERS’ SOCIETY

To recognize our generous donors who have made a commitment to the future of the Trudeau Institute through their estate planning, we have established The Founders’ Society. This vital component of the Institute’s advancement programs is our primary mechanism for building the endowment.

The Trudeau Institute gratefully acknowledges its supporters who, through their thoughtful planned gifts, enable our research to continue into the future. If you would like to include the Institute in your future estate plans, or have already, please notify us so that we ensure your wishes are met and acknowledged properly.

Members

Richard Baker*
James J. Barba
Ann Bickford*
Diana Bourke
Benjamin Brewster
Josephine T. Brune*
Isabel Collier Read*
Alfred Edwards Schlesinger*
Dorothy Swern Federman, M.D.
Jay Federman, M.D.
Henry A. Fenn, Jr.
Priscilla Goss
George T. Hartt*
Elizabeth P.S. Hawkins*
Lola Johnson
Raymond Johnson, Ph.D.
Barbara J. Kirstein*
Robert J. Lievense
Elizabeth Lowe
Barbara Matacotta
Helen C. Murray*
D. Dean Rhoads
Marcene S. Sonneborn
Linda Sturgis
Doris Tighe Coe*
Garry Trudeau
Ursula Wyatt Trudeau
Jeanne Trudeau Fenn
Harry Voege*

*Gift realized

We gratefully acknowledge all the federal employees who contributed through the Combined Federal Campaign to the Cancer and Aging Research Program at the Trudeau Institute.
Top: Trudeau employees and alumni gather at a reunion on July 19.
Lower: Nearly 40 people attended the first Global Health and Translational Sciences Summit in October 2018. Hosted by the Trudeau Research Network, the event drew representatives from nonprofit organizations such as the Bill and Melinda Gates Foundation, the federal government, and biotechnology and pharmaceutical companies.

Board of Trustees

Benjamin Brewster
Courtney Burke
Dorothy S. Federman, M.D.
Vincent A. Fischetti, Ph.D.
James C. Frauenthal, Ph.D.
Raymond N. Johnson, Ph.D.
Atsuo Kuki, Ph.D.
Daniel Leff
Airlie Cameron Lennon, M.D., MPH
Julie North
Michael J. Parker, M.D.
Brian A. Pollok, Ph.D.
Marcene Sonneborn
Konrad “Kip” Testwuide
Tielman T. Van Vleck, Ph.D.
Yi Xue

HONORARY TRUSTEES

James J. Barba
Frederick W. Beinecke
Alexander W. Dreyfous
Henry “Sandy” Fenn
Harry Jacobs Jr.
Lawrence L. Johnson, Ph.D.
David P. Kirstein
Robert J. North, Ph.D.
Alexander B. Trevor
Garry Trudeau
Ursula W. Trudeau
The 2018 Financial Report reflects positively on many of the initiatives underway at Trudeau. Our launch of Trudeau 3.0 is validated by a significant increase in contract revenue, fueled in part from the 20% increase in science staff over the past three years. We are on schedule to eliminate our debt service in 2020 while we expand our research and development capabilities to meet growing demand. Pending alliance revenue and continuing support from New York State will allow us to increase our science expenditures by 20% this coming year and expand our educational component, including hiring a Principal Investigator to lead our partnership with Clarkson University. Our collaborations with SUNY Upstate Medical University and Albert Einstein College of Medicine have strengthened the Trudeau Research Network (TRN), which is the centerpiece of Trudeau 3.0.

STATEMENT OF FINANCIAL POSITION
FISCAL YEARS ENDED DECEMBER 31

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>$1,360,523</td>
<td>$2,687,141</td>
</tr>
<tr>
<td>Grants receivable</td>
<td>6,214,051</td>
<td>4,041,066</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>$9,604,774</td>
<td>11,368,633</td>
</tr>
<tr>
<td>Other assets</td>
<td>285,294</td>
<td>324,319</td>
</tr>
<tr>
<td>Property, plant and equipment, net</td>
<td>$16,364,993</td>
<td>17,517,755</td>
</tr>
<tr>
<td>Funds held in trusts</td>
<td>3,248,454</td>
<td>3,694,684</td>
</tr>
<tr>
<td>TOTAL ASSETS</td>
<td>37,078,089</td>
<td>39,633,598</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable and accrued expenses</td>
<td>$494,242</td>
<td>290,031</td>
</tr>
<tr>
<td>Capital lease obligation</td>
<td>920,972</td>
<td>1,616,944</td>
</tr>
<tr>
<td>Loan payable</td>
<td>$375,000</td>
<td>675,000</td>
</tr>
<tr>
<td>TOTAL LIABILITIES</td>
<td>1,790,214</td>
<td>2,581,975</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available for operations</td>
<td>23,512,418</td>
<td>23,545,910</td>
</tr>
<tr>
<td>Internally designated/Edward C. Brewster Fund</td>
<td>$4,000,000</td>
<td>4,000,000</td>
</tr>
<tr>
<td>Total unrestricted</td>
<td>27,512,418</td>
<td>27,545,910</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$1,978,076</td>
<td>3,262,102</td>
</tr>
<tr>
<td>Permanently restricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endowments</td>
<td>$1,444,261</td>
<td>1,444,261</td>
</tr>
<tr>
<td>Funds held in trusts</td>
<td>3,248,454</td>
<td>3,694,684</td>
</tr>
<tr>
<td>Francis B. Trudeau Chair</td>
<td>$1,104,666</td>
<td>1,104,666</td>
</tr>
<tr>
<td>Total permanently restricted</td>
<td>5,797,381</td>
<td>6,243,611</td>
</tr>
<tr>
<td>TOTAL NET ASSETS</td>
<td>35,287,875</td>
<td>37,051,623</td>
</tr>
<tr>
<td>TOTAL LIABILITIES AND NET ASSETS</td>
<td>37,078,089</td>
<td>39,633,598</td>
</tr>
</tbody>
</table>
SENIOR MANAGEMENT
Atsuo Kuki, Ph.D.
President and Director
William B. Chapin, M.B.A.
Chief Administrative Officer/Controller
Perrin Babcock, M.A.
Director of Philanthropy

FACULTY
Marcia A. Blackman, Ph.D.
TRN Senior Principal Immunologist and
Leader, Viral Immunity Program
Trudeau Principal Investigator (Influenza,
Aging, Ferret & Vaccine Technologies)
Deborah Brown, Ph.D.
Manager, Joint Educational Programs
Trudeau Principal Investigator, Vaccine
Translational Science
In-Jeong Kim, Ph.D.
TRN Senior Immunologist and Leader,
Flavivirus Research Platform
Trudeau Principal Investigator, Vaccine
Translational Science
Jr-Shiu Lin, Ph.D.
TRN Research Scientist
Trudeau Principal Investigator
(Antibiotic-Resistant Bacteria [ARB]
and Select Agents)
William W. Reiley, Ph.D.
Chief Scientific Officer, TICRO BioServices
Trudeau Principal Investigator (Member, TB
and Influenza Program)
Felix Sheinerman, Ph.D.
Head of Chemogenomics
Trudeau Principal Investigator
Brian Weinrick, Ph.D.
TB R&D Program, Lead Investigator
Trudeau Principal Investigator

ADJUNCT PRINCIPAL INVESTIGATORS
Paras Jain, Ph.D.
Albert Einstein College of Medicine
Saravanan Thangamani, Ph.D.
SUNY Upstate Medical University

POSTDOCTORAL FELLOWS
Gaelle Guiewi, Ph.D.

SENIOR RESEARCH TECHNICIANS
Tres S. Cookenham III, A.A.S.
Debra K. Duso, A.A.S.
Kathleen G. Lanzer, B.S.
TRN Scientific Coordinator
Paula A. Lanthier, A.A.S.
Alan D. Roberts, B.S.
Frank M. Szaba, B.S., B.A.
Michael P. Tighe, A.A.S.
Head, Trudeau Imaging Core

RESEARCH TECHNICIANS
Derek Bernacki, B.S.
FACS Coordinator
Madeline Clark, M.S.
Laura Cole, B.S.
Mathew Cole, M.S.
TICRO, Lab Manager
Lawrence W. Kummer, B.S.
Tricia Lang, B.S.
Timothy Low-Beer, B.S.
Shania Muncil, B.S.
Kelsey Travis, B.S.

ANIMAL TECHNICAL SERVICES
Jenna Friers, B.S.
Animal Health/Veterinary Technician
Jody L. Hart, B.S.
Manager, Technical Services
ANIMAL HUSBANDRY
Nicole Beaudoin
Animal Care Technician 1
Lindsay Fagnano
Animal Care Technician 1
Jonathan A. Lauber
Animal Care Technician 2/ Sterilization Technician
Jill E. Miller, A.A.S.
Animal Care Technician 2
Natalie Miller, A.A.S.
Supervisor, EAM
Amanda A. Schneck, B.A.
Manager, Animal Facilities
Toni F. Vincent
Animal Facilities Clerk
William T. White
Animal Care Technician 2

HOUSEKEEPING
Timothy T. Harrigan, A.A.S.
Billi Jo Symonds
Housekeeping Supervisor
Kerry White

MAINTENANCE
David L. Benham
Maintenance Carpenter
Shawn R. Boyer
Boiler Operator
Michael Carter
Building Support Technician
Richard P. DeMerse
Maintenance
Earl F. Gardner
Machinist

Jon M. Law, Sr.
Manager, Facilities
Chad Mason
Electrician
Adam J. Mayville
Maintenance Technician
Bridget Parks, B.S.
Grounds Crew/Building Support Assistant

ADMINISTRATION
Charles T. Billingsley, B.S.
Manager, Computer Services
Suzanne M. Chapman, A.A.S.
Strategic Administrative Coordinator
Beth Devaney, A.A.S.
Staff Accountant/Accounts Payable
Kristofer Friers, B.S.
Systems Administrator
Kathleen Keck, M.B.A.
Executive Assistant to the President/Director
Linda M. Madon, B.F.A.
Payroll Specialist
David E. Martin, A.A.S.
Manager, Purchasing
Simone T. McConville, B.S.
Receptionist/Administrative Assistant
Jeremy Ressing, B.S., B.A.
Manager, Accounting
Lynn M. Ryan, B.A.
Manager, Occupational Health and Safety
Kelly Stanyon, M.L.S.
Associate Manager, Human Resources

Facing page: Members of Trudeau’s staff gather inside the Institute library.
Below: Members of the animal husbandry staff.

Photo credits: Split Rock Productions, Clarkson University, Mark Kurtz, Kathleen Keck.
TRUDEAU'S MISSION:

To safeguard human health and combat 21st century global health crises, from drug-resistant TB to emerging viruses and pandemics, by empowering specialized R&D pursuits in regional and global translational science partnerships.